New therapeutic options for the treatment of multiresistant bacteria in the ICU;Nuevas opciones terapéuticas para el tratamiento de las bacterias multirresistentes en Unidades de Cuidados Intensivos

Revista Espanola de Quimioterapia

Volumn 21, Issue SPEC. ISS. 1, 2008, Pages 9-13

  Gaite, Fernando Barcenilla ^a   Sáenz, A Jover ^a   Vidal, M Vallverdú ^a   Perelló, D Castellana ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

Daptomycin; Ertapenem; Linezolid; Multiresistant microorganisms; Therapeutic strategy; Tigecyclin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; DAPTOMYCIN; ERTAPENEM; LINEZOLID; MACROLIDE; METICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PSEUDOMONAS AERUGINOSA; RECOMMENDED DRUG DOSE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS;

EID: 54949120560     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. McGee A. News in antimicrobial resistance: documenting the progress of pathogens. Infect Control Hosp Epidemiol 2004;25: 97-8.
2. Livermore DM. Bacterial resistance: origins, epidemiology and impact. Clin Infect Dis 2003;36(Suppl. 1):S11-23.
3. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care units. Ann Intern Med 2001;134:298-314.
4. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-55.
5. Álvarez-Lerma F, Palomar M, Olaechea P, Otal JJ, Insausti J, Cerdá E. Estudio Nacional de Vigilancia de Infección Nosocomial en Unidades de Cuidados Intensivos. Informe evolutivo de los años 2003-2005. Med Intensiva 2007;3:6-17.
6. Lee SC, Hua CC, Ju TJ, Shieh WB, See LC. Risk factors of mortality for nosocomial pneumonia: importance of anti-microbial therapy. Int J Clin Pract 2005;59:39-45.
7. Khare M, Keady D. Antimicrobial therapy of methicillin-resistant Staphylococcus aureus infection. Expert Opin Pharmacother 2003;4:167-77.
8. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of Linezolid following multiple oral doses. Antimicrob Agents Chemother 2001;45:1843-6.
9. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42:1129-40.
10. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002;46:2723-6.
11. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49: 2260-6.
12. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-12.
13. Wunderink RG, Rello J, Cammarata SK, Cros-Davrera RV, Kollef MH. Linezolid vs vancomycin: análisis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-97.
14. Gómez J, Garcia Vázquez E, Baños R, Canteras M, Ruiz J, Baños V, et al. Predictors of mortality in patients with meticillin-resistant Staphylococcus aureus (MRSA) bacteremia: the role of empiric antibiotic therapy. Eur J Clin Microbiol Infect Dis 2007;26:239-45.
15. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003;52:538-42.
16. Paterson DL, Rossi F, Baquero F, Hsueh PR, Woods GL, Satishchandran V, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intraabdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005;55:965-73.
17. Elliott E, Brink AJ, Van Greune J, Els Z, Woodford N, Turton J, et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum β-lactamase. Clin Infect Dis 2006;42:e95-8.
18. DiNubile MJ, Friedland I, Chan CY, Motyl MR, Giezek H, Shivaprakash M, et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis 2005;24:443-9.
19. Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003;237:235-45.
20. Roy S, Higareda I, Angel-Muller E, Ismail M, Hague C, Adeyi B, et al. Ertapenem once a day versus piperacillin-tazobactam every 6 hors for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study. Infect Dis Obstet Gynecol 2003;11:27-37.
21. Ortiz-Ruiz G, Caballero-López J, Friedland IR, Woods GL, Carides A. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002;34:1076-83.
22. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infec Dis 2005;41:S333-40.
23. Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005;49:4658-66.
24. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infec Dis 2005;41:S354-67.
25. Tally FP, DeBruin MJ. Development of daptomycin for gram-positive infections. J Antimicrob Chemother 2000;46:523-6.
26. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structureinfections. Clin Infect Dis 2004;38:1673-81.
27. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:724-7.
28. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149-52.
29. Lentino JR, Narita M, Yu VL. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis 2008;27:3-15.
30. Raad I, Darouiche R, Vázquez J, Lentnek A, Hachem R, Hanna H, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005;40:374-80.
31. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003;37:1298-303.
32. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. Drugs 2007: 67:1027-52.
33. Anderson DL. Doripenem. Drugs Today (Barc) 2006;42:399-404.